GleamWall
中文EN

SRRK Scholar Rock Holding Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1727196 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-17.0%
TTM EPS YoY-2.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-71,732.3%
Net margin-72,563.2%
FCF margin-54,370.7%
EBITDA margin-71,501.6%

Returns

ROE-200.0%
ROA-96.4%
ROIC (approx.)-1,144.3%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets62.2%
Debt / equity1.16x
Current ratio5.41x
Interest coverage-29.23x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-24.2%
Payout ratio—
Capex / revenue35.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$570,000$0$0$0$0———
Cost of revenue$8,000———$0———
Gross profit$562,000———$0———
R&D expense$54.13M$58.23M$51.81M$46.88M$50.49M$62.40M$48.68M$50.37M
SG&A expense$52.49M$50.67M$50.20M$45.02M$53.06M$49.71M$28.41M$18.99M
Operating income-$106.06M-$108.90M-$102.02M-$91.90M-$103.55M-$112.11M-$77.09M-$69.36M
Interest expense$4.63M$4.52M$2.30M$2.53M$1.33M$1.21M$1.82M$1.41M
Net income-$107.24M-$109.90M-$105.51M-$90.97M-$102.22M-$110.03M-$74.72M-$66.45M
EBITDA-$105.80M-$108.60M-$101.68M-$91.47M-$103.13M-$111.69M-$76.70M-$68.96M
EPS (basic)-0.81-0.84-0.83—-0.90-0.98-0.67—
EPS (diluted)-0.81-0.84-0.83—-0.90-0.98-0.67—
Weighted avg. shares (diluted)132.37M130.61M127.28M—113.73M112.70M111.84M—
Balance sheet
Cash & equivalents$366.27M$437.09M$430.54M$323.53M$286.77M$152.93M$137.93M$180.28M
Short-term investments$47.33M$55.00M$49.40M$44.04M$82.86M$142.09M$226.45M$259.40M
Receivables$677,000——$0————
Inventory$773,000——$0————
Current assets$433.43M$507.18M$515.28M$385.15M$390.71M$319.13M$385.25M$451.17M
PP&E, net$984,000$1.17M$1.44M$1.71M$2.12M$2.44M$2.64M$2.76M
Total assets$445.97M$523.54M$535.25M$404.27M$411.72M$340.05M$407.55M$474.92M
Current liabilities$80.12M$72.24M$59.64M$55.42M$61.97M$50.44M$37.57M$46.94M
Long-term debt$196.21M$196.20M$196.61M$99.71M$99.61M$49.76M$49.74M$50.15M
Total debt$196.21M$196.20M$196.61M$99.71M$99.61M$49.76M$49.74M$50.15M
Total liabilities$277.30M$269.76M$259.24M$158.78M$166.72M$106.75M$95.22M$106.29M
Shareholders' equity$168.68M$253.78M$276.01M$245.49M$245.00M$233.29M$312.33M$368.63M
Net debt-$170.06M-$240.89M-$233.93M-$223.82M-$187.16M-$103.17M-$88.19M-$130.14M
Shares outstanding121.93M121.60M119.10M108.46M99.17M96.00M94.87M93.82M
Cash flow statement
Operating cash flow-$81.81M-$70.31M-$82.10M-$75.50M-$68.92M-$76.94M-$78.67M-$49.51M
Capital expenditure$101,000$1,000$68,000$32,000$84,000$215,000$271,000$22,000
Free cash flow-$81.91M-$70.31M-$82.17M-$75.53M-$69.01M-$77.16M-$78.95M-$49.53M
Investing cash flow$7.94M-$5.50M-$5.33M$38.97M$59.70M$85.47M$34.55M-$195.37M
Financing cash flow$3.13M$83.12M$193.79M$73.29M$144.47M$6.47M$4.17M$346.37M
Depreciation & amortization$258,000$297,000$335,000$425,000$423,000$417,000$393,000$395,000
Stock-based compensation$17.91M$19.66M$18.25M$19.42M$18.33M$24.43M$13.41M$9.50M

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.